Fraxiparine

País: Nova Zelanda

Idioma: anglès

Font: Medsafe (Medicines Safety Authority)

ingredients actius:

Nadroparin calcium 9500 anti-Xa IU/mL

Disponible des:

Pharmacy Retailing (NZ) Ltd t/a Healthcare Logistics

Designació comuna internacional (DCI):

Nadroparin calcium 9500 anti-Xa IU/mL

Dosis:

9500 anti-Xa IU/mL

formulario farmacéutico:

Solution for injection

Composición:

Active: Nadroparin calcium 9500 anti-Xa IU/mL Excipient: Calcium hydroxide Hydrochloric acid Water for injection

Unidades en paquete:

Syringe, glass, prefilled syringe 0.6ml x 2, 2 dose units

clase:

Prescription

tipo de receta:

Prescription

Fabricat per:

Glaxo Wellcome Production

indicaciones terapéuticas:

Prophylaxis against thromboembolic disorders, especially those associated with general or orthopaedic surgery. Treatment of thromboembolic disorders. Prevention of clotting during haemodialysis.

Resumen del producto:

Package - Contents - Shelf Life: Syringe, glass, prefilled syringe 0.6ml x 2 - 2 dose units - 36 months from date of manufacture stored at or below 25°C - Syringe, glass, prefilled syringe 0.4ml x 2 - 2 dose units - 36 months from date of manufacture stored at or below 25°C - Syringe, glass, prefilled syringe 0.3ml x 2 - 2 dose units - 36 months from date of manufacture stored at or below 25°C - Syringe, glass, prefilled syringe 0.2ml x 2 - 2 dose units - 36 months from date of manufacture stored at or below 25°C - Syringe, glass, prefilled syringe 0.3ml x 10 - 10 dose units - 36 months from date of manufacture stored at or below 25°C - Syringe, glass, prefilled syringe 1ml x 10 - 10 dose units - 36 months from date of manufacture stored at or below 25°C - Syringe, glass, prefilled syringe 0.8ml x 10 - 10 dose units - 36 months from date of manufacture stored at or below 25°C - Syringe, glass, prefilled syringe 0.6ml x 10 - 10 dose units - 36 months from date of manufacture stored at or below 25°C - Syringe, glass, prefilled syringe 0.4ml x 10 - 10 dose units - 36 months from date of manufacture stored at or below 25°C - Syringe, glass, prefilled syringe 0.2ml x 10 - 10 dose units - 36 months from date of manufacture stored at or below 25°C

Data d'autorització:

1994-02-09

Fitxa tècnica

Medsafe Logo
The sponsor (pharmaceutical company) of this
product has advised Medsafe that this product has
either been discontinued or is no longer marketed in
New Zealand.
Therefore this Data Sheet may not be up to date.
Medsafe has elected to leave it on this web site
because supplies of this product may still be
available, and health professionals should continue
to have access to this product information in the
interim.
You may be able to find a more current Data Sheet
containing the same medicine by returning to the
main Data Sheet page and searching by ingredient
name.
INFORMATION FOR
HEALTH PROFESSIONALS
Home  |  Consumers  |  Health Professionals  |  Regulatory  |  Other  |  Hot Topics  |  Search
Data Sheet
Fraxiparine
®
INJECTION
Nadroparin Calcium 9,500 IU anti-Xa
(AXa) per 1.0 mL solution for injection.

Presentation
Fraxiparine is a sterile, clear preservative-free solution usually for subcutaneous injection containing
Nadroparin Calcium 9,500 IU AXa per 1.0 mL dissolved in water for injections.
Fraxiparine is a low molecular weight heparin made by depolymerisation of standard heparin. It is a
glycosaminoglycan with a mean molecular weight around 4,500 daltons. It possesses a high ratio of
anti-Xa activity to anti-IIa activity. Fraxiparine has both immediate and prolonged antithrombotic action.
Uses
Actions
Low molecular weight heparin.
Pharmacokinetics
Pharmacokinetics have been determined by measurement of plasma anti-Xa activity. The plasma peak
Pharmacokinetics have been determined by measurement of plasma anti-Xa activity. The plasma peak
occurs about 3 hours after subcutaneous injection. The elimination half-life is about 3.5 hours. Anti-Xa
activity persists for at least 18 hours after injection.
Bioavailability is almost complete (around 98%).
A